Method for inhibiting cancer using arsenic trioxide
AssigneeThe University of Hong Kong
InventorYok-Lam Kwong
Life of this patent
Estimating the term…
Abstract
The invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering a composition containing an effective amount of arsenic trioxide to an affected patient. The arsenic trioxide can be administered orally, for example, as a solution, suspension, syrup, emulsion, tablet, or capsule. The composition can also contain one or more pharmaceutically acceptable carriers and/or excipients.
Claims13
A method for inhibiting cyclin D1 production in a cell, comprising contacting the cell with an amount of arsenic trioxide effective to inhibit cyclin D1 production therein.
A unit dosage form for oral administration comprising arsenic trioxide in a pharmaceutically acceptable carrier for enteral administration.
A unit dosage form for oral administration comprising arsenic trioxide in a pharmaceutically acceptable carrier for enteral administration, wherein the dosage form contains a sufficient amount of arsenic trioxide to deliver a dose in the range of 5 to 10 mg.
Dependencies are inferred from the claim text.